This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to developdrugs and vaccines for RSV with these populations in mind.
Since the first human administration of the Bacillus Calmette-Guérin vaccine in 1921, no one has been able to successfully follow the vaccine’s path to become the next approved vaccine to tackle tuberculosis (TB). However, as the TB-related death toll remains high, the global need for another vaccine is steadily rising.
Instead of starting with ‘what equipment do we have’, we’re really starting with our end goal by considering what is required by the drugdevelopers,” explains Lenaerts. This is something that sets Datwyler’s approach apart from its competitors. Lessons from the Pandemic: Building a Better Prefilled Syringe. By Datwyler.
Since most biologics and biosimilars are large molecules, they may prove challenging to develop and manufacture on the large scale. However, the adoption of automation in the lab setting can set the stage for a pilot phase to drive optimisation and efficiency into a new era of drugdevelopment and manufacturing.
We are delighted to deepen our partnership with Teddy Lab that will enable us to build on existing knowledge and increase services within China to support customers with their global drugdevelopment programmes. Teddy Lab has been a trusted partner for many years and mirrors our commitment to high-quality, patient-centric solutions.
On the other hand, a lack of diversity in clinical trial populations, particularly when the disease population is significantly underrepresented, greatly diminishes the quality of data obtained for drug safety and efficacy profiles. This may sound obvious, but it is still a major hurdle in drugdevelopment.
Several drugdevelopment trends are driving injectables demand. This includes the rising number of biologic drugs on the market, which are mostly administered parenterally. During the Covid-19 pandemic, large-scale vaccine production placed unprecedented demand on the parenteral packaging industry.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content